Predictors of Atherosclerosis in Ankylosing Spondylitis

Rheumatology and Therapy

Volumn 2, Issue 2, 2015, Pages 173-182

  Verma, Inderjeet ^a   Krishan, Pawan ^a   Syngle, Ashit ^b  

^a PUNJABI UNIVERSITY   (India)

^b Rheumatologist Fortis Multi Specialty Hospital   (India)

Author keywords

Ankylosing spondylitis; Atherosclerosis; Carotid intima media thickness; Inflammatory cytokines

Indexed keywords

EID: 84996426529     PISSN: 21986576     EISSN: 21986584     Source Type: Journal    
DOI: 10.1007/s40744-015-0017-8     Document Type: Article

References (34)

1. Berg IJ, van der Heijde D, Dagfinrud H, et al. Disease activity in ankylosing spondylitis and associations to markers of vascular pathology and traditional cardiovascular disease risk factors: a cross sectional study. J Rheumatol. 2015;42:645–53. DOI: 10.3899/jrheum.141018
2. Peters MJ, van der Horst-Bruinsma IE, Dijkmans BA, Nurmohamed MT. Cardiovascular risk profile of patients with spondyl arthropathies, particularly ankylosing spondylitis and psoriatic arthritis. Semin Arthritis Rheum. 2004;34:585–92. DOI: 10.1016/j.semarthrit.2004.07.010
3. John H, Kitas G. Inflammatory arthritis as a novel risk factor for cardiovascular risk. Eur J Intern Med. 2012;23:575–9. DOI: 10.1016/j.ejim.2012.06.016
4. Mathieu S, Gossec L, Dougados M, Soubrier M. Cardiovascular profile in ankylosing spondylitis: a systematic review and meta-analysis. Arthritis Care Res (Hoboken). 2011;63:557–63. DOI: 10.1002/acr.20364
5. Wofford JL, Kahl FR, Howard GR, McKinney WM, Toole JF, Crouse JR III. Relation of extent of extracranialarotid artery atherosclerosis as measured by B-mode ultrasound to the extent of coronary atherosclerosis. Arterioscler Thromb. 1991;11:1786–94. DOI: 10.1161/01.ATV.11.6.1786
6. van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum. 1984;27:361–8. DOI: 10.1002/art.1780270401
7. Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults. Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA. 2001;285:2486–97. DOI: 10.1001/jama.285.19.2486
8. Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol. 1994;21:2286–91.
9. van der Heijde D, Lie E, Kvien TK, Sieper J, Van den Bosch F, Listing J, et al. ASDAS, a highly discriminatory ASAS-endorsed disease activity score in patients with ankylosing spondylitis. Ann Rheum Dis. 2009;68:1811–8. DOI: 10.1136/ard.2008.100826
10. Calin A, Garrett S, Whitelock H, Kennedy LG, O”Hea J, Mallorie P, Jenkinson T. A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. J Rheumatol. 1994;21:2281–5.
11. Huang K, Zou CC, Yang XZ, et al. Carotid intima media thickness and serum endothelial marker levels in obese children with metabolic syndrome. Arch Pediatr Adolesc Med. 2010;164:846–51.
12. Gonzalez-Gay MA, Gonzalez-Juanatey C, Martin J. Rheumatoid arthritis: a disease associated with accelerated atherogenesis. Semin Arthritis Rheum. 2005;35:8–17. DOI: 10.1016/j.semarthrit.2005.03.004
13. Gonzalez-Juanatey C, Llorca J, Amigo-Diaz E, Dierssen T, Martin J, Gonzalez-Gay MA. High prevalence of subclinical atherosclerosis in psoriatic arthritis patients without clinically evident cardiovascular disease or classic atherosclerosis risk factors. Arthrtis Rheum. 2007;1557:1074–80. DOI: 10.1002/art.22884
14. Hahn BH, Grossman J, Chen W, McMahon M. The pathogenesis of atherosclerosis in autoimmune rheumatic diseases: roles of inflammation and dyslipidemia. J Autoimmun. 2007;28:69–75. DOI: 10.1016/j.jaut.2007.02.004
15. Bots ML, Grobbee DE. Intima media thickness as a surrogate marker for generalized atherosclerosis. Cardiovasc Drugs Ther. 2002;16:341–51. DOI: 10.1023/A:1021738111273
16. Bots ML, Evans GW, Riley WA, Grobbee DE. Carotid intima media thickness measurements in intervention studies design options, progression rates, and sample size considerations: a point of view. Stroke. 2003;34:2985–94. DOI: 10.1161/01.STR.0000102044.27905.B5
17. Gonzalez-Juanatey C, Vazquez-Rodriguez TR, Miranda-Filloy JA, et al. The high prevalence of subclinical atherosclerosis in patients with ankylosing spondylitis without clinically evident cardiovascular disease. Medicine (Baltimore). 2009;88:358–65. DOI: 10.1097/MD.0b013e3181c10773
18. Peters MJ, van Eijk IC, Smulders YM, et al. Signs of accelerated preclinical atherosclerosis in patients with ankylosing spondylitis. J Rheumatol. 2010;37:161–6. DOI: 10.3899/jrheum.090667
19. Cece H, Yazgan P, Karakas E, Karakas O, Demirkol A, Toru I, Aksoy N. Carotid intima-media thickness and paraoxonase activity in patients with ankylosing spondylitis. Clin Invest Med. 2011;1(34):E225.
20. Skare TL, Verceze GC, Oliveira AA, Perreto S. Carotid intima-media thickness in spondyloarthritis patients. Sao Paulo Med J. 2013;131:100–5.
21. Perrotta FM, Scarno A, Carboni A, Bernardo V, Montepaone M, Lubrano E. Assessment of subclinical atherosclerosis in ankylosing spondylitis: correlations with disease activity indices. Rheumatismo. 2013;23:105–12.
22. Ozsahin M, Buyukkaya R, Besir FH, et al. Assessment of carotid intima-media thickness in ankylosing spondylitis patients. Acta Med Mediterr. 2013;29:687–92.
23. Gupta N, Saigal R, Goyal L, Agarwal A, Bhargava R, Agarwal A. Carotid intima media thickness as a marker of atherosclerosis in ankylosing spondylitis. Int J Rheumatol. 2014;2014:839135. DOI: 10.1155/2014/839135
24. Hamdi W, ChelliBouaziz M, Zouch I, et al. Assessment of preclinical atherosclerosis in patients with ankylosing spondylitis. J Rheumatol. 2012;39:322–6. DOI: 10.3899/jrheum.110792
25. Choe JY, Lee MY, Rheem I, Rhee MY, Park SH, Kim SK. No difference of carotid intima-media thickness between young patients with ankylosing spondylitis and healthy controls. Joint Bone Spine. 2008;75:548–53. DOI: 10.1016/j.jbspin.2007.11.007
26. Mathieu S, Joly H, Baron G, et al. Trend towards increased arterial stiffness or intima-media thickness in ankylosing spondylitis patients without clinically evident cardiovascular diseases. Rheumatology (Oxford). 2008;47:1203–7. DOI: 10.1093/rheumatology/ken198
27. Verma S, Wang CH, Li SH, et al. A self-fulfilling prophecy: C-reactive protein attenuates nitric oxide production and inhibits angiogenesis. Circulation. 2002;106:913–9. DOI: 10.1161/01.CIR.0000029802.88087.5E
28. Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med. 1999;340:448–54. DOI: 10.1056/NEJM199902113400607
29. Buckley DI, Fu R, Freeman M, Rogers K, Helfand M. C-reactive protein as a risk factor for coronary heart disease: a systematic review and meta-analyses for the US Preventive Services Task Force. Ann Intern Med. 2009;151:483–95. DOI: 10.7326/0003-4819-151-7-200910060-00009
30. Sattar N, Mc Carey DW, Capell H, McInnes IB. Explaining how “high-grade” systemic inflammation accelerates vascular risk in rheumatoid arthritis. Circulation. 2003;108:2957–63. DOI: 10.1161/01.CIR.0000099844.31524.05
31. van Eijk IC, Peters MJ, Serne EH, et al. Microvascular function is impaired in ankylosing spondylitis and improves after tumor necrosis factor α blockade. Ann Rheum Dis. 2009;68:362–6. DOI: 10.1136/ard.2007.086777
32. Syngle A, Vohra K, Sharma A, Kaur L. Endothelial dysfunction in ankylosing spondylitis improves after tumor necrosis factor-alpha blockade. Clin Rheumatol. 2010;29:763–70. DOI: 10.1007/s10067-010-1402-x
33. Del Porto F, Lagana B, Lai S, et al. Response to anti-tumour necrosis factor alpha blockade is associated with reduction of carotid intima-media thickness in patients with active rheumatoid arthritis. Rheumatology (Oxford). 2007;46:1111–5. DOI: 10.1093/rheumatology/kem089
34. Di Minno MN, Lervolino S, Peluso R, Scarpa R, Di Minno G, CaRRDs study Group. Carotid intima-media thickness in psoriatic arthritis differences between tumor necrosis factor-α blockers and traditional disease-modifying antirheumatic drugs. Arterioscler Thromb Vasc Biol. 2011;31:705–12. DOI: 10.1161/ATVBAHA.110.214585